2005
Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology
McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B. Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal Of Psychiatry 2005, 162: 1142-1148. PMID: 15930063, DOI: 10.1176/appi.ajp.162.6.1142.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsAutistic DisorderChildCommunication DisordersConduct DisorderDouble-Blind MethodFemaleHumansInterpersonal RelationsMalePersonality InventoryPlacebosPsychiatric Status Rating ScalesRisperidoneStereotyped BehaviorStereotypic Movement DisorderTreatment OutcomeConceptsYale-Brown Obsessive Compulsive ScaleChildren's Yale-Brown Obsessive Compulsive ScaleRitvo-Freeman Real Life Rating ScaleObsessive Compulsive ScaleBehavior domainsVineland Adaptive Behavior ScalesCompulsive ScaleCore symptom domainsAdaptive Behavior ScalesSensory-motor behaviorsSelf-injurious behaviorCommunicative impairmentsAutistic childrenSocial relatednessAutism NetworkRating ScaleCommunication impairmentsSevere tantrumsCore symptomsBehavior ScaleSocial interactionAutistic disorderAutismSymptom domainsLife Rating ScaleSudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone
Scahill L, Blair J, Leckman JF, Martin A. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. Journal Of Psychopharmacology 2005, 19: 205-206. PMID: 15728441, DOI: 10.1177/0269881105049042.Peer-Reviewed Original ResearchAdultAntipsychotic AgentsCholesterolDeath, SuddenFatal OutcomeHumansMalePiperazinesPsychiatric Status Rating ScalesThiazolesTourette Syndrome
2003
Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder
Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV. Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder. American Journal Of Psychiatry 2003, 160: 1919-1928. PMID: 14594734, DOI: 10.1176/appi.ajp.160.11.1919.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsObsessive-compulsive disorderStandardized mean differenceOutcome measuresMean differenceStudy designSerotonin reuptake inhibitorsDependent outcome measuresAdolescent obsessive-compulsive disorderSystematic literature searchMultivariate regression analysisPediatric obsessive-compulsive disorderTypes of drugsEffect sizePlacebo treatmentMedication trialsReuptake inhibitorsOutcome scoresPharmacological treatmentPharmacotherapy trialsOverall effect sizeInclusion criteriaClinical careDrug effectsMeta-AnalysisDRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study
Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D, Gothelf D, Nahshoni E, Tyano S, Weizman A. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European Neuropsychopharmacology 2003, 13: 183-185. PMID: 12729944, DOI: 10.1016/s0924-977x(03)00006-3.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScalePossible associationAdolescent schizophrenia patientsFirst-episode schizophreniaPsychiatric Rating ScaleHigh response rateClinical responseRepeat alleleSchizophrenia patientsResponse rateSignificant associationPharmacogenetic studiesRisperidoneAdolescent inpatientsRating ScaleSchizophreniaAssociationDRD4 genotypeDRD4 geneResponseIsraeli adolescentsLarge groupPolymorphismDRD4 exon III polymorphismPatients